Multitherapeutic contract research partners can promise a great deal to their potential clients—access to vast resources, flexibility, and multiple skill sets within their organization. And in some cases, that might be a good fit for sponsoring a clinical trial. But in other cases, partnering with multitherapeutic contract research partners can ultimately be costly in time, money, and data quality.
Put simply, a jack-of-all-trades organization might not be the best fit when your outcomes require specific needs and critical endpoints. For sponsors researching products that are dedicated to specific and critical conditions, including oncology and orphan disease, it’s far more important for a partner to have specific expertise and experience.
It’s important to remember that a contract research organization (CRO) ultimately has to keep its people billable, and as such, it assigns individuals where it has the most need. As a transition from the “A” team to the “B” team takes place to complete a study, the quality of service and data is ultimately compromised.
In the end, while some CROs can offer a wide array of resources and flexibility and could work well in some projects, it boils down to assigning the right people to work on a study…average resources going where they’re assigned, as opposed to highly skilled experts.
More About Multitherapeutic Contract Research Partners
For a much more detailed breakdown of multitherapeutic contract research partners and whether they are a good fit for your efforts in clinical trials, take a look at this detailed PDF, featuring specifics and statistics regarding the impact of different types of outsourcing organizations.
inSeption Group offers full-service outsourcing focused on oncology, hematology, neurodegenerative disorders, and rare/orphan disease with a specialization in cell and gene therapy. Contact inSeption Group today to find out more about our services, and follow inSeption Group on LinkedIn for the latest updates.
